ChemicalBook

639089-54-6(Tozasertib) Product Description

Tozasertib Structure639089-54-6
CAS No.639089-54-6
Chemical Name:Tozasertib
CBNumber:CB51513746
Molecular Formula:C23H28N8OS
Formula Weight:464.59
MOL File:Mol file
Tozasertib Synonyms:
Cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino) -pyrimidin-2ylsulphanyl]-phenyl}-amide
VX-680/MK-0457
N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(1-methylpiperidin-4-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide
MK 0457
N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide
Tozasertib
VX 680
Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-

Tozasertib Property

Melting point: 248-253°C (dec.)
Density  1.40±0.1 g/cm3(Predicted)
storage temp.  2-8°C
solubility  Soluble in DMSO (up to 100 mg/ml).
pka 14.09±0.70(Predicted)
form  powder
color  white to beige
Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.

Safety

Tozasertib Suppliers

Global( 197)Suppliers     
SupplierTelEmailCountryProdListAdvantage
TargetMol Chemicals Inc. +1-781-999-5354marketing@targetmol.comUnited States 31976 58
Shanghai SuperLan Chemcial Technique Centre 021-2022843681chaolaichem@foxmail.comChina 7879 58
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd. 17702719238sales@sun-shinechem.comChina 960 64
TargetMol Chemicals Inc. 021-021-33632979marketing@targetmol.comChina 7783 58
SHANGHAI KEAN TECHNOLOGY CO., LTD.  cooperation@kean-chem.comChina 40066 58
Bide Pharmatech Ltd. 400-1647117product02@bidepharm.comChina 62163 58
Hebei Fengjia New Material Co., Ltd +86-0311-87836622sales06@hbduling.cn China 8054 58
Shanghai klamar Reagent Co., LTD 40016509003003940895@qq.comChina 10716 58
639089-54-6(Tozasertib) Related Search:
Cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino) -pyrimidin-2ylsulphanyl]-phenyl}-amide VX-680/MK-0457 N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(1-methylpiperidin-4-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide MK 0457 N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide Tozasertib VX 680 Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)- N-(4-(4-(5-Methyl-1H-pyrazol-3-ylamino)-6-(1-methylpiperidin-4-ylamino)pyrimidin-2-ylthio)phen N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide Tozasertib N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide VX-680(Tozasertib) Tozasertib(MK-0457,VX-680) VX-860 Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide L-001281814 Tozasertib/VX-680 N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide VX-680 (MK-0457)(Tozasertib) Tozasertib￡VX680￡MK0457 Tozasertib Free Base N-[4-[[4-(4-Methylpiperazin-1-yl)-6-[(5-Methyl-1H-pyrazol-3-yl)aMino]pyriMidin-2-yl]thio]phenyl]cyclopropanecarboxaMide VX-680 (Tozasertib, MK-0457) VX680;MK0457;VX 680 (MK 0457;TOZASERTIB) CS-176 VE 465 VE465 VE-465 VX680; VX 680; VX-680; MK0457; MK 0457; MK-0457; VE465; VE-465; VE 465; TOZASERTIB TOZASERTIB;MK-0457;MK0457;VX680;VX 680;MK 0457 N-[4-({4-[(3-METHYL-1H-PYRAZOL-5-YL)AMINO]-6-(4-METHYLPIPERAZIN-1-YL)PYRIMIDIN-2-YL}SULFANYL)PHENYL]CYCLOPROPANECARBOXAMIDE tozasertib (MK-0457) MK-0457,Tozasertib Tozasertib USP/EP/BP N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide MK-0457 Tozasertib VX-680 639089-54-6 C24H30N8OS C23H28N8OS Inhibitors A multikinase inhibitor. Inhibitor Aromatics Heterocycles Intermediates & Fine Chemicals Mutagenesis Research Chemicals Pharmaceuticals
Copyright 2017 © ChemicalBook. All rights reserved